Clinical usefulness of WT1 mRNA expression in bone marrow detected by a new WT1 mRNA assay kit for monitoring acute myeloid leukemia: a comparison with expression of WT1 mRNA in peripheral blood

International Journal of Hematology

Volumn 103, Issue 1, 2016, Pages 53-62

  Kitamura, Kunio ^a   Nishiyama, Takahiro ^a,g   Ishiyama, Ken ^b,p   Miyawaki, Shuichi ^b   Miyazaki, Kanji ^c   Suzuki, Kenshi ^c   Masaie, Hiroaki ^d   Okada, Masaya ^e   Ogawa, Hiroyasu ^e   Imai, Kiyotoshi ^f   Kiyoi, Hitoshi ^g   Naoe, Tomoki ^g,q   Yokoyama, Yasuhisa ^h   Chiba, Shigeru ^h   Hata, Tomoko ⁱ   Miyazaki, Yasushi ⁱ   Hatta, Yoshihiro ^j   Takeuchi, Jin ^j,r   Nannya, Yasuhito ^k   Kurokawa, Mineo ^k   Ueda, Yasunori ^l   Koga, Daisuke ^m   Sugiyama, Haruo ⁿ   Takaku, Fumimaro ^o   more..

^a Ichinomiya Municipal Hospital   (Japan)

^b Tokyo Metropolitan Ohtsuka Hospital   (Japan)

^c JAPANESE RED CROSS MEDICAL CENTER   (Japan)

^d OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^e HYOGO COLLEGE OF MEDICINE   (Japan)

^f SAPPORO HOKUYU HOSPITAL   (Japan)

^g NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^h UNIVERSITY OF TSUKUBA   (Japan)

ⁱ NAGASAKI UNIVERSITY   (Japan)

^j NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k UNIVERSITY OF TOKYO   (Japan)

^l KURASHIKI CENTRAL HOSPITAL   (Japan)

^m OTSUKA PHARMACEUTICAL CO LTD   (Japan)

ⁿ OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^o Japan Medical Association   (Japan)

^p KANAZAWA UNIVERSITY HOSPITAL   (Japan)

^q NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^r Hachioji Medical Center   (Japan)

more..

Author keywords

Acute myeloid leukemia; Bone marrow; Myelodysplastic syndromes; One step real time RT PCR; WT1 mRNA

Indexed keywords

GENOMIC DNA; MESSENGER RNA; WT1 PROTEIN; DIAGNOSTIC KIT; WT1 PROTEIN, HUMAN;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW; CANCER PATIENT; CROSS REACTION; DIAGNOSTIC KIT; FEMALE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYELODYSPLASTIC SYNDROME; VERY ELDERLY; WT1 MRNA ASSAY KIT II; BLOOD; COMPARATIVE STUDY; GENETICS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; PHYSIOLOGIC MONITORING; PROCEDURES; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BONE MARROW; FEMALE; GENE EXPRESSION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; REAGENT KITS, DIAGNOSTIC; RNA, MESSENGER; WT1 PROTEINS; YOUNG ADULT;

EID: 84954381023     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-015-1882-1     Document Type: Article

References (17)

1. Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber DA, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms’ tumor locus. Cell. 1990;60:509–20.
2. Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, Bruns GA. Homozygous deletion in Wilms tumors of a zinc-finger gene identified by chromosome jumping. Nature. 1990;343:774–8.
3. Rauscher FJ 3rd. The WT1 Wilms tumor gene product: a developmentally regulated transcription factor in the kidney that functions as a tumor suppressor. FASEB J. 1993;7:896–903.
4. Inoue K, Sugiyama H, Ogawa H, Nakagawa M, Yamagami T, Miwa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood. 1994;84:3071–9.
5. Oji Y, Ogawa H, Tamaki H, Oka Y, Tsuboi A, Kim EH, et al. Expression of the Wilms’ tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res. 1999;90:194–204.
6. Sugiyama H. Wilms’ tumor gene WT1: its oncogenic function and clinical application. Int J Hematol. 2001;73:177–87.
7. Inoue K, Ogawa H, Yamagami T, Soma T, Tani Y, Tatekawa T, et al. Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels. Blood. 1996;88:2267–78.
8. Miyawaki S, Emi N, Mitani K, Oyashiki K, Kitamura K, Morishita T. Clinical course of the disease and the level of WT1 mRNA in patients with acute myeloid leukemia (AML): joint research by 23 institutions in Japan. Jpn J Clin Hematol. 2005;46(12):1279–87.
9. Trka J, Kalinová M, Hrusák O, Zuna J, Krejcí O, Madzo J, et al. Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry. Leukemia. 2002;16(7):1381–9.
10. Cilloni D, Gottardi E, De Micheli D, Serra A, Volpe G, Messa F, et al. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia. 2002;16(10):2115–21.
11. Tamaki H, Mishima M, Kawakami M, Tsuboi A, Kim EH, Hosen N, et al. Monitoring minimal residual disease in leukemia using real-time quantitative polymerase chain reaction for Wilms tumor gene (WT1). Int J Hematol. 2003;78(4):349–56.
12. Østergaard M, Olesen LH, Hasle H, Kjeldsen E, Hokland P. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70 % of acute myeloid leukaemia patients—results from a single-centre study. Br J Haematol. 2004;125:590–600.
13. Weisser M, Kern W, Rauhut S, Schoch C, Hiddemann W, Haferlach T, et al. Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia. 2005;19:1416–23.
14. Kitamura K, Nakano Y, Watamoto K, Koga D, Naoe T. Significance of monitoring WT1 mRNA levels of peripheral blood and bone marrow in acute myeloid leukemia. Jpn J Clin Hematol. 2010;51(12):1748–55.
15. Cilloni D, Renneville A, Hermitte F, Hills RK, Daly S, Jovanovic JV, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WTl assay to enhance risk stratification in acute myeloid leukemia: a European leukemia net study. J Clin Oncol. 2009;27(31):5195–201.
16. Miyawaki S, Hatsumi N, Tamaki T, Naoe T, Ozawa K, Kitamura K, et al. Prognostic potential of detection of WT1 mRNA level in peripheral blood in adult acute myeloid leukemia. Leuk Lymphoma. 2010;51(10):1855–61.
17. Ommen HB, Nyvold CG, Braendstrup K, Andersen BL, Ommen IB, Hasle H, et al. Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals. Br J Haematol. 2008;141(6):782–91.